Abstract:BACKGROUND Osteoporosis (OP) has become a major public health problem worldwide. Most OP treatments are based on the inhibition of bone resorption, and it is necessary to identify additional treatments aimed at enhancing osteogenesis. In the bone marrow (BM) niche, bone mesenchymal stem cells (BMSCs) are exposed to a hypoxic environment. Recently, a few studies have demonstrated that hypoxia-inducible factor 2alpha (HIF-2α) is involved in BMSC osteogenic differentiation, but the molecular mechanism involved has not been determined. AIM To investigate the effect of HIF-2α on the osteogenic and adipogenic differentiation of BMSCs and the hematopoietic function of hematopoietic stem cells (HSCs) in the BM niche on the progression of OP. METHODS Mice with BMSC-specific HIF-2α knockout (Prx1-Cre;Hif-2αfl/fl mice) were used for in vivo experiments. Bone quantification was performed on mice of two genotypes with three interventions: Bilateral ovariectomy, semilethal irradiation, and dexamethasone treatment. Moreover, the hematopoietic function of HSCs in the BM niche was compared between the two mouse genotypes. In vitro , the HIF-2α agonist roxadustat and the HIF-2α inhibitor PT2399 were used to investigate the function of HIF-2α in BMSC osteogenic and adipogenic differentiation. Finally, we investigated the effect of HIF-2α on BMSCs via treatment with the mechanistic target of rapamycin (mTOR) agonist MHY1485 and the mTOR inhibitor rapamycin. RESULTS The quantitative index determined by microcomputed tomography indicated that the femoral bone density of Prx1-Cre;Hif-2αfl/fl mice was lower than that of Hif-2αfl/fl mice under the three intervention conditions. In vitro , Hif-2αfl/fl mouse BMSCs were cultured and treated with the HIF-2α agonist roxadustat, and after 7 d of BMSC adipogenic differentiation, the oil red O staining intensity and mRNA expression levels of adipogenesis-related genes in BMSCs treated with roxadustat were decreased; in addition, after 14 d of osteogenic differentiation, BMSCs treated with roxadustat exhibited increased expression of osteogenesis-related genes. The opposite effects were shown for mouse BMSCs treated with the HIF-2α inhibitor PT2399. The mTOR inhibitor rapamycin was used to confirm that HIF-2α regulated BMSC osteogenic and adipogenic differentiation by inhibiting the mTOR pathway. Consequently, there was no significant difference in the hematopoietic function of HSCs between Prx1-Cre;Hif-2αfl/fl and Hif-2αfl/fl mice. CONCLUSION Our study showed that inhibition of HIF-2α decreases bone mass by inhibiting the osteogenic differentiation and increasing the adipogenic differentiation of BMSCs through inhibition of mTOR signaling in the BM niche.

HIF-1α Disturbs Osteoblasts and Osteoclasts Coupling in Bone Remodeling by Up-Regulating OPG Expression

[Regulation of Hypoxia Inducible Factor-1Alpha on Osteoblast Function in Osteogenesis].

Osteocytic HIF-1α Pathway Manipulates Bone Micro-structure and Remodeling via Regulating Osteocyte Terminal Differentiation

HIF-1α Regulates Bone Homeostasis and Angiogenesis, Participating in the Occurrence of Bone Metabolic Diseases

Osteoblast Hypoxia-Inducible Factor-1 Alpha Pathway Activation Restrains Osteoclastogenesis Via The Interleukin-33-Microrna34a-Notch1 Pathway

The hypoxia-inducible factor α pathway couples angiogenesis to osteogenesis during skeletal development

Differential but complementary roles of HIF-1α and HIF-2α in the regulation of bone homeostasis

RhoA Promotes Osteoclastogenesis and Regulates Bone Remodeling Through Mtor-Nfatc1 Signaling.

Spatiotemporal correlation between HIF-1 alpha and bone regeneration

Regulation of Interaction of Osteoblasts and Osteoclasts by Hypoxia/hypoxiainducible Factor-1Α Pathway

Osteoblast-secreted Factors Promote Proliferation and Osteogenic Differentiation of Bone Marrow Stromal Cells Via VEGF/heme-oxygenase-1 Pathway.

Hypoxia-inducible factor 1α enhances RANKL-induced osteoclast differentiation by upregulating the MAPK pathway

Activation of HIFa pathway in mature osteoblasts disrupts the integrity of the osteocyte/canalicular network.

[The regulation of hypoxia inducible factor-1alpha on osteoblast function in postmenopausal osteoporosis]

Synergistic Inhibition of Wnt Pathway by HIF-1α and Osteoblast-Specific Transcription Factor Osterix (osx) in Osteoblasts

Hif-1 Alpha Inhibits Wnt Signaling Pathway By Activating Sost Expression In Osteoblasts

Activation of the Hypoxia-Inducible Factor-1 Alpha Pathway Accelerates Bone Regeneration

Unveiling the role of hypoxia-inducible factor 2alpha in osteoporosis: Implications for bone health

Oxygen sensing and osteogenesis

HIF-1α Inhibits Wnt Signaling Pathway by Activating Sost Expression in Osteoblasts

Mice with Increased Angiogenesis and Osteogenesis Due to Conditional Activation of Hif Pathway in Osteoblasts Are Protected from Ovariectomy Induced Bone Loss